Noticias

DaVita’s first quarter results were met with a strongly positive market reaction, reflecting operational execution and ongoing cost control. Management attributed the quarter’s outperformance to balanced gains across treatment volume, revenue per treatment, and cost management, aided by productivity improvements and favorable patient outcomes. CEO Javier Rodriguez highlighted the continued momentum of the company’s Integrated Kidney Care (IKC) business, which delivered year-over-year improvement

NXST, LCUT and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 14th, 2026.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

DaVita has outpaced the broader market over the past year, with Wall Street analysts maintaining a cautiously optimistic outlook on the stock’s long-term prospects.

A Communications Equipment Company Showing Promise as a Solid Momentum Pick and a Medical Company with Strong Growth Characteristics.

HIMS reports an adjusted loss and a revenue miss in first-quarter 2026 as gross margin decreases, but it lifts its full-year revenue outlook.

Rosarium Health, a Black-founded healthtech company supporting in-home care for aging populations, has secured new funding.

AR, DVA and WOOF made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 12th, 2026.